Home Newsfeeds JMP Securities Reiterates Market Outperform on Backblaze, Maintains $18 Price Target

JMP Securities Reiterates Market Outperform on Backblaze, Maintains $18 Price Target

JMP Securities analyst Erik Suppiger reiterates Backblaze (NASDAQ:BLZE) with a Market Outperform and maintains $18 price target.

byBenzinga Newsdesk

February 22, 2023

1 minute read

JMP Securities analyst Erik Suppiger reiterates Backblaze (NASDAQ:BLZE) with a Market Outperform and maintains $18 price target.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $6,800 Today

By Benzinga Insights

January 31, 2:33 PM

Tyson Foods (NYSE:TSN) has outperformed the market over the past 20 years by 1.98% on an annualized basis…

TSN

Here’s How Much Amazon’s Ads Business Is Willing To Pay For Top Talent

By Bibhu Pattnaik

December 9, 7:08 PM

Following a temporary hiring freeze, Amazon.com Inc (NASDAQ: AMZN) has significantly accelerated its recruitment for Amazon Ads, its rapidly growing advertis

AMZN

Kineta Announces First Patient Dosed In Phase 1/2 VISTA-101 Clinical Trial Of KVA12123 In Combination With KEYTRUDA In Patients With Advanced Solid Tumors

By Benzinga Newsdesk

October 17, 8:40 AM

The Combination Arm (Part B) of the Phase 1/2 Clinical Trial Builds Upon the Initial Safety, Tolerability and Pharmacokinetic Data of KVA12123 in the Monotherapy Arm (Part A)Initial Combination Therapy Clinical Data

News

Biora Therapeutics Enhances Financial Position Through $50M Equity Swap Agreement with Athyrium Capital

By Benzinga Newsdesk

September 19, 8:09 AM

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced an agreement with certain funds managed by Athyrium Capital Management, to increase their equity

BIOR

JMP Securities Reiterates Market Outperform on Backblaze, Maintains $18 Price Target

Related Posts

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $6,800 Today

Here’s How Much Amazon’s Ads Business Is Willing To Pay For Top Talent

Kineta Announces First Patient Dosed In Phase 1/2 VISTA-101 Clinical Trial Of KVA12123 In Combination With KEYTRUDA In Patients With Advanced Solid Tumors

Biora Therapeutics Enhances Financial Position Through $50M Equity Swap Agreement with Athyrium Capital